BioCentury | Jan 7, 2021
Finance

Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest

...Returning investors from its $56 million series A are Longwood Fund, Taiho Ventures, Arkin Bio Ventures, UPMC Enterprises...
BioCentury | Oct 24, 2020
Emerging Company Profile

SparingVision’s line of sight to a mutation-agnostic gene therapy for ophthalmic disease

...tranche Wednesday led by 4BIO Capital and UPMC Enterprises...
...Blindness, Foundation Voir & Entendre, Jeito Capital, UPMC Enterprises...
BioCentury | Jan 15, 2020
Financial News

UPMC venture arm to invest $1B in up to 50 life sciences companies

...investments will likely go towards companies with technologies that are not linked with the university. UPMC Enterprises...
BioCentury | Nov 20, 2019
Financial News

Werewolf debuts with $56M to develop tumor-activated biologics

...Capital and Longwood Fund co-led the round with participation from Taiho Ventures, Arkin Bio Ventures, UPMC Enterprises...
BioCentury | Oct 11, 2019
Product Development

What’s next for neoantigens

...helmed by serial biotech executive David Apelian, raised a $10 million series A round from UPMC Enterprises...
BioCentury | Jul 31, 2019
Company News

Apelian to lead new T cell company BlueSphere

...in 2017 based on their TCXpress platform, which the company has licensed from the university. UPMC Enterprises...
BioCentury | Jun 13, 2016
Financial News

Omicia completes venture financing

...Oakland, Calif. Business: Bioinformatics Date completed: 2016-06-08 Type: Venture financing Raised: $23 million Investors: UPMC Enterprises...
BioCentury | Jun 9, 2016
Financial News

Genomics play Omicia raises $23M

...Calif.) raised $23 million in a series B round. New investors in the round included UPMC Enterprises...
Items per page:
1 - 8 of 8
BioCentury | Jan 7, 2021
Finance

Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest

...Returning investors from its $56 million series A are Longwood Fund, Taiho Ventures, Arkin Bio Ventures, UPMC Enterprises...
BioCentury | Oct 24, 2020
Emerging Company Profile

SparingVision’s line of sight to a mutation-agnostic gene therapy for ophthalmic disease

...tranche Wednesday led by 4BIO Capital and UPMC Enterprises...
...Blindness, Foundation Voir & Entendre, Jeito Capital, UPMC Enterprises...
BioCentury | Jan 15, 2020
Financial News

UPMC venture arm to invest $1B in up to 50 life sciences companies

...investments will likely go towards companies with technologies that are not linked with the university. UPMC Enterprises...
BioCentury | Nov 20, 2019
Financial News

Werewolf debuts with $56M to develop tumor-activated biologics

...Capital and Longwood Fund co-led the round with participation from Taiho Ventures, Arkin Bio Ventures, UPMC Enterprises...
BioCentury | Oct 11, 2019
Product Development

What’s next for neoantigens

...helmed by serial biotech executive David Apelian, raised a $10 million series A round from UPMC Enterprises...
BioCentury | Jul 31, 2019
Company News

Apelian to lead new T cell company BlueSphere

...in 2017 based on their TCXpress platform, which the company has licensed from the university. UPMC Enterprises...
BioCentury | Jun 13, 2016
Financial News

Omicia completes venture financing

...Oakland, Calif. Business: Bioinformatics Date completed: 2016-06-08 Type: Venture financing Raised: $23 million Investors: UPMC Enterprises...
BioCentury | Jun 9, 2016
Financial News

Genomics play Omicia raises $23M

...Calif.) raised $23 million in a series B round. New investors in the round included UPMC Enterprises...
Items per page:
1 - 8 of 8